

Michael S Niederman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7320939/publications.pdf>

Version: 2024-02-01

112
papers

11,544
citations

76196

40
h-index

29081

104
g-index

130
all docs

130
docs citations

130
times ranked

10119
citing authors

#	ARTICLE	IF	CITATIONS
1	Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. <i>Clinical Infectious Diseases</i> , 2007, 44, S27-S72.	2.9	5,203
2	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. <i>European Respiratory Journal</i> , 2017, 50, 1700582.	3.1	792
3	Linezolid in Methicillin-Resistant <i>Staphylococcus aureus</i> Nosocomial Pneumonia: A Randomized, Controlled Study. <i>Clinical Infectious Diseases</i> , 2012, 54, 621-629.	2.9	513
4	Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 677.	3.8	428
5	Aspiration Pneumonia. <i>New England Journal of Medicine</i> , 2019, 380, 651-663.	13.9	363
6	Pneumonia Complicating Pregnancy. <i>Clinics in Chest Medicine</i> , 2011, 32, 121-132.	0.8	235
7	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021, 7, 25.	18.1	230
8	Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. <i>BMJ: British Medical Journal</i> , 2010, 340, c1004-c1004.	2.4	225
9	Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 316-325.	1.3	147
10	Microbiology of Ventilator-Associated Pneumonia Compared With That of Hospital-Acquired Pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 825-831.	1.0	145
11	BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. <i>Intensive Care Medicine</i> , 2012, 38, 263-271.	3.9	144
12	Ventilator-associated pneumonia: present understanding and ongoing debates. <i>Intensive Care Medicine</i> , 2015, 41, 34-48.	3.9	138
13	Use of Broad-Spectrum Antimicrobials for the Treatment of Pneumonia in Seriously Ill Patients: Maximizing Clinical Outcomes and Minimizing Selection of Resistant Organisms. <i>Clinical Infectious Diseases</i> , 2006, 42, S72-S81.	2.9	116
14	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. <i>Intensive Care Medicine</i> , 2013, 39, 672-681.	3.9	114
15	A New Strategy for Healthcare-Associated Pneumonia: A 2-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-Resistant Pathogens to Select Initial Empiric Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 1373-1383.	2.9	108
16	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. <i>Chest</i> , 2020, 158, 1896-1911.	0.4	105
17	Challenges in severe community-acquired pneumonia: a point-of-view review. <i>Intensive Care Medicine</i> , 2019, 45, 159-171.	3.9	100
18	Etiology of Community-Acquired Pneumonia in Hospitalized Patients in Chile. <i>Chest</i> , 2007, 131, 779-787.	0.4	97

#	ARTICLE	IF	CITATIONS
19	Appropriate use of antimicrobial agents: Challenges and strategies for improvement. <i>Critical Care Medicine</i> , 2003, 31, 608-616.	0.4	96
20	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 330-340.	4.6	88
21	Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Chest</i> , 2016, 150, 415-425.	0.4	85
22	Community-acquired pneumonia related to intracellular pathogens. <i>Intensive Care Medicine</i> , 2016, 42, 1374-1386.	3.9	85
23	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). <i>European Respiratory Review</i> , 2020, 29, 200287.	3.0	82
24	Hospital-Acquired Pneumonia, Health Care-Associated Pneumonia, Ventilator-Associated Pneumonia, and Ventilator-Associated Tracheobronchitis: Definitions and Challenges in Trial Design. <i>Clinical Infectious Diseases</i> , 2010, 51, S12-S17.	2.9	75
25	Recent Advances in Community-Acquired Pneumonia. <i>Chest</i> , 2007, 131, 1205-1215.	0.4	71
26	Biological Markers to Determine Eligibility in Trials for Community-Acquired Pneumonia: A Focus on Procalcitonin. <i>Clinical Infectious Diseases</i> , 2008, 47, S127-S132.	2.9	69
27	The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1519-1526.	1.5	69
28	Updates on community acquired pneumonia management in the ICU. , 2021, 217, 107663.		68
29	The delivery of futile care is harmful to other patients. <i>Critical Care Medicine</i> , 2010, 38, S518-S522.	0.4	65
30	Antibiotic Stewardship in the Intensive Care Unit. An Official American Thoracic Society Workshop Report in Collaboration with the AACN, CHEST, CDC, and SCCM. <i>Annals of the American Thoracic Society</i> , 2020, 17, 531-540.	1.5	63
31	Making sense of scoring systems in community acquired pneumonia. <i>Respirology</i> , 2009, 14, 327-335.	1.3	59
32	Initial antimicrobial management of sepsis. <i>Critical Care</i> , 2021, 25, 307.	2.5	58
33	Principles of appropriate antibiotic use. <i>International Journal of Antimicrobial Agents</i> , 2005, 26, S170-S175.	1.1	56
34	De-escalation therapy in ventilator-associated pneumonia. <i>Current Opinion in Critical Care</i> , 2006, 12, 452-457.	1.6	55
35	Future Research Directions in Pneumonia. NHLBI Working Group Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 256-263.	2.5	54
36	Is a Strategy Based on Routine Endotracheal Cultures the Best Way to Prescribe Antibiotics in Ventilator-Associated Pneumonia?. <i>Chest</i> , 2013, 144, 63-71.	0.4	48

#	ARTICLE	IF	CITATIONS
37	The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. <i>Chest</i> , 2020, 158, 1008-1016.	0.4	46
38	Outcomes and Prognostic Features of Patients With Influenza Requiring Hospitalization and Receiving Early Antiviral Therapy. <i>Chest</i> , 2016, 149, 526-534.	0.4	44
39	Community-Acquired Pneumonia: The U.S. Perspective. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 179-188.	0.8	43
40	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. <i>European Respiratory Journal</i> , 2015, 45, 1353-1363.	3.1	42
41	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , 2018, 4, 00028-2018.	1.1	41
42	De-Escalation Therapy: Is It Valuable for the Management of Ventilator-Associated Pneumonia?. <i>Clinics in Chest Medicine</i> , 2011, 32, 517-534.	0.8	40
43	Editorial: The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 193-196.	1.2	40
44	The Argument against Using Quantitative Cultures in Clinical Trials and for the Management of Ventilator-Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2010, 51, S93-S99.	2.9	38
45	Community-Acquired Pneumonia Guidelines: A Global Perspective. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 298-310.	0.8	38
46	A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy. <i>Clinical Infectious Diseases</i> , 2019, 68, 1080-1088.	2.9	37
47	Randomized, multicenter trial of lateral Trendelenburg versus semirecumbent body position for the prevention of ventilator-associated pneumonia. <i>Intensive Care Medicine</i> , 2017, 43, 1572-1584.	3.9	36
48	Effect of Combined β -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2019, 155, 795-804.	0.4	34
49	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. <i>Expert Review of Vaccines</i> , 2021, 20, 243-256.	2.0	33
50	The Importance of De-escalating Antimicrobial Therapy in Patients with Ventilator-Associated Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2006, 27, 045-050.	0.8	32
51	Rising to the Challenge of COVID-19: Advice for Pulmonary and Critical Care and an Agenda for Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1019-1022.	2.5	32
52	The clinical diagnosis of ventilator-associated pneumonia. <i>Respiratory Care</i> , 2005, 50, 788-96; discussion 807-12.	0.8	29
53	Characterization of <i>Pseudomonas aeruginosa</i> Adherence to Cultured Hamster Tracheal Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1991, 5, 563-570.	1.4	27
54	Management of pneumonia in critically ill patients. <i>BMJ</i> , The, 2021, 375, e065871.	3.0	27

#	ARTICLE	IF	CITATIONS
55	Macrolide-Resistant Pneumococcus in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy?. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1216-1217.	2.5	25
56	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. PLoS ONE, 2017, 12, e0178022.	1.1	25
57	Health Economic Evaluation of Patients Treated for Nosocomial Pneumonia Caused by Methicillin-resistant Staphylococcus aureus: Secondary Analysis of a Multicenter Randomized Clinical Trial of Vancomycin and Linezolid. Clinical Therapeutics, 2014, 36, 1233-1243.e1.	1.1	24
58	Review of treatment guidelines for community-acquired pneumonia. The American Journal of Medicine: Supplement, 2004, 117, 51-57.	1.7	21
59	Acute lower respiratory infections in developing countries. Lancet, The, 2013, 381, 1341-1342.	6.3	20
60	Treatment options for nosocomial pneumonia due to MRSA. Journal of Infection, 2009, 59, S25-S31.	1.7	18
61	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2021, 18, 1087-1097.	1.5	17
62	Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 732-741.	2.0	16
63	Aspiration pneumonia. Revista Espanola De Quimioterapia, 2022, 35, 73-77.	0.5	16
64	Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Current Medical Research and Opinion, 2004, 20, 749-756.	0.9	15
65	Predicting mortality in the elderly with community-acquired pneumonia: should we design a new car or set a new 'speed limit'?. Thorax, 2010, 65, 944-945.	2.7	15
66	Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. Current Medical Research and Opinion, 2004, 20, 969-980.	0.9	14
67	Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. European Respiratory Journal, 2016, 48, 257-261.	3.1	13
68	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. Chest, 2017, 151, 1311-1319.	0.4	13
69	Challenges in the Management of Community-Acquired Pneumonia: The Role of Quinolones and Moxifloxacin. Clinical Infectious Diseases, 2005, 41, S158-S166.	2.9	12
70	Antibiotic treatment of hospital-acquired pneumonia: is it different from ventilator-associated pneumonia?. Current Opinion in Critical Care, 2018, 24, 353-360.	1.6	12
71	Adjunctive Nebulized Antibiotics: What Is Their Place in ICU Infections?. Frontiers in Medicine, 2019, 6, 99.	1.2	12
72	Can optimal management prevent mortality in ventilator-associated pneumonia?*. Critical Care Medicine, 2002, 30, 1916-1917.	0.4	12

#	ARTICLE	IF	CITATIONS
73	Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. <i>Expert Review of Vaccines</i> , 2021, 20, 257-267.	2.0	10
74	Using Ventilator-Associated Pneumonia Rates as a Health Care Quality Indicator: A Contentious Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 237-244.	0.8	10
75	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e74-e87.	4.6	10
76	Managing Ventilator Complications in a VACuum of Data. <i>Chest</i> , 2015, 147, 5-6.	0.4	9
77	The research agenda in VAP/HAP: next steps. <i>Intensive Care Medicine</i> , 2017, 43, 1389-1391.	3.9	8
78	Imaging for the Management of Community-Acquired Pneumonia. <i>Chest</i> , 2018, 153, 583-585.	0.4	8
79	Real life management of community-acquired Pneumonia in adults in the Gulf region and comparison with practice guidelines: a prospective study. <i>BMC Pulmonary Medicine</i> , 2015, 15, 112.	0.8	7
80	Predictors of Clinical Success in the Treatment of Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Nosocomial Pneumonia (NP). <i>PLoS ONE</i> , 2015, 10, e0131932.	1.1	7
81	Bacteraemia in outpatients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016, 47, 654-657.	3.1	7
82	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , 2019, 8, 1461.	1.0	7
83	Principles of Antibiotic Management of Community-Acquired Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 905-912.	0.8	6
84	Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021, 18, 807-814.	1.5	4
85	Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by <i>Staphylococcus aureus</i> : Post Hoc Analysis of 2 Randomized, Controlled Trials. <i>Infectious Diseases and Therapy</i> , 2019, 8, 445-452.	1.8	3
86	Natural enemy or friend? Pneumonia in the very elderly critically ill patient. <i>European Respiratory Review</i> , 2020, 29, 200031.	3.0	3
87	Antibiotic Use in Sepsis: How and Why Less Can Really Mean More (Survival). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 157-158.	2.5	3
88	Editorial: Coronavirus disease 2019 (COVID-19) – advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 141-145.	1.2	3
89	How low can we go in community-acquired pneumonia therapy?. <i>Lancet</i> , The, 2021, 397, 1160-1161.	6.3	3
90	Too Much or Too Little Empiric Treatment for <i>Pseudomonas aeruginosa</i> in Community-acquired Pneumonia?. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1456-1458.	1.5	3

#	ARTICLE	IF	CITATIONS
91	The road forward in the management of Acinetobacter infections in the ICU. Intensive Care Medicine, 2015, 41, 2207-2209.	3.9	2
92	Serum procalcitonin and the admission decision in CAP. Lancet Respiratory Medicine, the, 2016, 4, 956.	5.2	2
93	Pneumonia Complicating COPD: Are Corticosteroids a Help or a Hindrance?. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 1-4.	0.5	2
94	Letter from the United States. Respirology, 2020, 25, 900-902.	1.3	2
95	Preparing for the Unexpected. Chest, 2013, 143, 287-289.	0.4	1
96	Lessons learned from 2 decades of CAP therapy data: ways to improve patient management. Journal of Thoracic Disease, 2016, 8, E455-E459.	0.6	1
97	Understanding community-acquired respiratory tract infections. Current Opinion in Pulmonary Medicine, 2016, 22, 193-195.	1.2	1
98	New Strategies to Prevent Ventilator-Associated Pneumonia: What to Do for Your Patients. Current Treatment Options in Infectious Diseases, 2016, 8, 1-15.	0.8	1
99	Beat around the bush for VA-LRTI. Intensive Care Medicine, 2018, 44, 1961-1963.	3.9	1
100	Clinical Impact of Antimicrobial Resistance. Chest, 2019, 155, 1088-1089.	0.4	1
101	Update in Lung Infections and Tuberculosis 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 414-422.	2.5	1
102	24th International Symposium on Infections in the Critically Ill Patient. Medical Sciences (Basel,) Tj ETQqO 0 0 rgBT /Qverlock_10 Tf 50 30	1.3	1
103	Editorial. Current Opinion in Pulmonary Medicine, 2019, 25, 217-219.	1.2	1
104	The INHALE trial: multiple reasons for a negative result – Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 779-780.	4.6	1
105	What COVID-19 Has Taught Us: Ventilator-associated Pneumonia Is Back!. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 132-134.	2.5	1
106	Title is missing!. Sepsis, 1998, 1, 153-159.	0.5	0
107	Î²-Lactams in the Therapy of Community-Acquired Pneumonia. , 0 , 153-169.		0
108	Reply to Yamamoto et al. Clinical Infectious Diseases, 2014, 58, 1040-1041.	2.9	0

#	ARTICLE	IF	CITATIONS
109	Ventilator-associated pneumonia prevention: response to Silvestri et al.. Intensive Care Medicine, 2015, 41, 957-957.	3.9	0
110	Respiratory Infections: An Ongoing Challenge with a Promising Future. Clinics in Chest Medicine, 2018, 39, xv-xvi.	0.8	0
111	Consensus (CORE) versus Systematic (GRADE) Approach to Development of Guidelines for Community-Acquired Pneumonia. Clinical Infectious Diseases, 2020, 73, e1476-e1477.	2.9	0
112	Community-acquired pneumonia. Israel Medical Association Journal, 2003, 5, 133-8.	0.1	0